OSE Immunotherapeutics - Another partnership with expansion into CAR-T

OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with the Memorial Sloan Kettering Cancer Center (MSK), focused on chimeric antigen receptor (CAR)-T cell therapies. OSE and MSK were already engaged in an ongoing research collaboration for a preclinical non-antagonist interleukin-7 receptor (IL-7R) monoclonal antibody to be used either as a therapeutic or for the design of CAR-T cell therapies. The new agreement specifically covers patent rights for CAR-T cell therapies targeting IL-7R expressing cancers. While precise details have not been disclosed, MSK will assume responsibility for research, development and commercialisation, and will share future potential revenue with OSE. Management also provided an update on the recent progress of its messenger RNA (mRNA) platform, highlighting the potential of an mRNA therapeutic using lipid nanoparticles in autoimmune hepatitis. OSE announced a series of partnerships in recent months that provide external validation of its capabilities in developing innovative therapies across various modalities for indications with unmet medical needs.